Zobrazeno 1 - 10 of 2 173 pro vyhledávání: '"Ryan CW"'
5
Akademický článek
A Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: Vulvar Cancers.
Autor: Chae YK; Northwestern University Feinberg School of Medicine, Chicago, IL, United States., Corthell L; Fred Hutchinson Cancer Center, United States., Patel SP; UC San Diego Health System, La Jolla, United States., Edwards R; University of Pittsburgh, Pittsburgh, United States., Scalici JM; Winship Cancer Institute, Atlanta, GA, United States., Kim HS; Temple University Hospital, Philadelphia, PA, United States., Chung LI; Northwestern University Feinberg School of Medicine, Chicago, IL, United States., Othus M; Fred Hutchinson Cancer Center, Seattle, WA, United States., McLeod CM; SWOG Data Operations Center, United States., Chen HX; National Cancer Institute, Bethesda, MD, United States., Sharon E; National Cancer Institute, Bethesda, MD, United States., Streicher H; National Cancer Institute, Rockville, MD, United States., Ryan CW; Oregon Health & Science University, Portland, OR, United States., Blanke CD; Oregon Health & Science University, Portland, OR, United States., Kurzrock R; Worldwide Innovative Network (WIN) for Personalized Cancer Therapy, Villejuif, France.
Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Nov 19. Date of Electronic Publication: 2024 Nov 19.
Zobrazit plný text záznamu
6
Akademický článek
A phase 4, multicenter, global clinical study to evaluate discontinuation and rechallenge of pexidartinib in patients with tenosynovial giant cell tumor previously treated with pexidartinib.
Autor: Desai J; Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia., Wagner AJ; Dana-Farber Cancer Institute, Center for Sarcoma and Bone Oncology, Boston, Massachusetts, USA., Carrasco Garcia I; Virgen del Rocio University Hospital, Seville, Spain., Cesari M; Rizzoli Orthopedic Institute, Bologna, Italy., Gordon M; HonorHealth Research Institute, Scottsdale, Arizona, USA., Lin CC; National Taiwan University Hospital, Taipei, Taiwan., Papai Z; Semmelweis University, Budapest, Hungary., Ryan CW; Oregon Health & Science University, Portland, Oregon, USA., Tap WD; Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, New York, USA., Trent JC; Sylvester Comprehensive Cancer Center, University of Miami Health System, Miami, Florida, USA., Gelderblom H; Leiden University Medical Center, Leiden, Netherlands., Grimison P; Chris O'Brien Lifehouse, Sydney, New South Wales, Australia., López Pousa A; Hospital of the Holy Cross and Saint Paul, Barcelona, Spain., Van Tine BA; Siteman Cancer Center and Washington University School of Medicine, St Louis, Missouri, USA., Rubinacci M; Daiichi Sankyo, Inc., Basking Ridge, New Jersey, USA., Dai D; Daiichi Sankyo, Inc., Basking Ridge, New Jersey, USA., Rajper AW; Daiichi Sankyo, Inc., Basking Ridge, New Jersey, USA., Tecson K; Daiichi Sankyo, Inc., Basking Ridge, New Jersey, USA., Wooddell M; Daiichi Sankyo, Inc., Basking Ridge, New Jersey, USA., Stacchiotti S; Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Publikováno v: Cancer [Cancer] 2024 Nov 12. Date of Electronic Publication: 2024 Nov 12.
Zobrazit plný text záznamu
7
Akademický článek
A novel interaction between RNA m 6 A methyltransferase METTL3 and RREB1.
Autor: Xu J; Department of Ophthalmology and Visual Science, W.K. Kellogg Eye Center, University of Michigan, Ann Arbor, MI, 48105, USA., Sivakumar C; Department of Ophthalmology and Visual Science, W.K. Kellogg Eye Center, University of Michigan, Ann Arbor, MI, 48105, USA; Department of Pathology, University of Michigan, Ann Arbor, MI, 48105, USA., Ryan CW; Medical Scientist Training Program, University of Michigan, Medical School, Ann Arbor, MI, 48105, USA., Rao RC; Department of Ophthalmology and Visual Science, W.K. Kellogg Eye Center, University of Michigan, Ann Arbor, MI, 48105, USA; Department of Pathology, University of Michigan, Ann Arbor, MI, 48105, USA; Department of Human Genetics, University of Michigan, Ann Arbor, MI, 48105, USA; Rogel Cancer Center, University of Michigan, Ann Arbor, MI, 48105, USA; Center of Computational Medicine and Bioinformatics, University of Michigan, Ann Arbor, MI, 48105, USA; Center for RNA Biomedicine, University of Michigan, Ann Arbor, 48105, USA; A. Alfred Taubman Medical Research Institute, University of Michigan, Ann Arbor, MI, 48105, USA; Section of Ophthalmology, Surgical Service, Veterans Administration Ann Arbor Healthcare System, Ann Arbor, MI, 48105, USA. Electronic address: rajeshr@med.umich.edu.
Publikováno v: Biochemical and biophysical research communications [Biochem Biophys Res Commun] 2024 Nov 12; Vol. 733, pp. 150668. Date of Electronic Publication: 2024 Sep 10.
Zobrazit plný text záznamu
8
Editorial & Opinion
Adjuvant everolimus after renal cell carcinoma nephrectomy - Authors' reply.
Autor: Ryan CW; Oregon Health and Science University Knight Cancer Institute, Portland, OR 97239, USA. Electronic address: ryanc@ohsu.edu., Tangen CM; SWOG Statistics and Data Management Center, Seattle, WA, USA., Lara PN Jr; University of California Davis Comprehensive Cancer Center, Sacramento, CA, USA.
Publikováno v: Lancet (London, England) [Lancet] 2024 Nov 09; Vol. 404 (10465), pp. 1810.
Zobrazit plný text záznamu
9
Akademický článek
SWOG/NCI Phase II Dual Anti-CTLA-4/PD-1 Blockade in Rare Tumors (DART): Non-Epithelial Ovarian Cancer.
Autor: Chae YK; Northwestern University Feinberg School of Medicine, Chicago, IL, United States., Othus M; Fred Hutchinson Cancer Center, Seattle, WA, United States., Patel SP; UC San Diego Health System, La Jolla, United States., Wilkinson KJ; University of Mississippi Medical Center, United States., Whitman-Purves EM; The Mark H. Zangmeister Center/Columbus NCORP, United States., Lea J; UT Southwestern, Dallas, United States., Schallenkamp JM; Billings Clinic Cancer Center/Montana NCORP, United States., Adra N; Indiana University School of Medicine, Indianapolis, IN, United States., Appleman LJ; University of Pittsburgh, Pittsburgh, PA, United States., Alden M; Doylestown Hospital, Thomas Jefferson University, Doylestown, PA, United States., Thomes Pepin J; Indiana University Bloomington, United States., Ellerton JA; Nevada Cancer Research Foundation, United States., Poklepovic A; Virginia Commonwealth University, Richmond, VA, United States., Walter A; ProMedica, Toledo, OH, United States., Rampurwala MM; University of Chicago Medicine, United States., Robinson WR; Tulane Medical Center, New Orleans, LA, United States., Kim HS; Temple University Hospital, Philadelphia, PA, United States., Chung LI; Northwestern University Feinberg School of Medicine, Chicago, IL, United States., McLeod CM; SWOG Data Operations Center, United States., Lopez G; Fred Hutchinson Cancer Center, Seattle, WA, United States., Chen HX; National Cancer Institute, Bethesda, MD, United States., Sharon E; National Cancer Institute, Bethesda, MD, United States., Streicher H; National Cancer Institute, Rockville, MD, United States., Ryan CW; Oregon Health & Science University, Portland, OR, United States., Blanke CD; Oregon Health & Science University, Portland, OR, United States., Kurzrock R; Worldwide Innovative Network (WIN) for Personalized Cancer Therapy, Villejuif, France.
Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Oct 17. Date of Electronic Publication: 2024 Oct 17.
Zobrazit plný text záznamu
10
Akademický článek
Phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: the desmoid tumors.
Autor: Chae YK; Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA chaelabmeeting@gmail.com., Othus M; Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.; SWOG Statistics and Data Management Center, SWOG, Seattle, Washington, USA., Patel S; University of California San Diego Moores Cancer Center, La Jolla, California, USA., Powers B; The University of Kansas Cancer Center, Overland Park, Kansas, USA., Hsueh CT; Loma Linda University Cancer Center, Loma Linda, California, USA., Govindarajan R; University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA., Bucur S; St Luke's Cancer Institute, Meridian, Idaho, USA., Kim HS; Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.; Medicine, Temple University Hospital, Philadelphia, PA, USA., Chung LI; Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA., McLeod C; SWOG Data Operations Center, Seattle, Washington, USA., Chen HX; Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland, USA., Sharon E; Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland, USA.; Dana-Farber Cancer Center, Boston, Massachusetts, USA., Streicher H; Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland, USA., Ryan CW; Oregon Health & Science University, Portland, Oregon, USA., Blanke C; SWOG Group Chair's Office, Knight Cancer Institute, Portland, OR, USA., Kurzrock R; Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
Publikováno v: Journal for immunotherapy of cancer [J Immunother Cancer] 2024 Sep 28; Vol. 12 (9). Date of Electronic Publication: 2024 Sep 28.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje